N eurogenesis has been studied extensively in the last decade (see reviews 1, 2 ). Neural stem/progenitor cells proliferate in the subventricular zone (SVZ) and the subgranular zone of the hippocampus. New cells migrate from the SVZ to the olfactory bulb via the rostral migratory stream and differentiate into neurons and glia. [3] [4] [5] Cells from the subgranular zone migrate a short distance to the granule cell layer of the dentate gyrus. 6 -8 Some newly formed neurons integrate functionally into the neuronal circuitry. 9, 10 Glial cells produced within germinal zones may also participate in injury response and repair. 11 Neurons are produced following injuries such as targeted ablation of cortical neurons, 12 gross trauma, 13 or stroke. 14 -16 This "reactive neurogenesis" may be more successful when tissue destruction and inflammation are minimized. Arvidsson et al 17 reported that only 20% of the cells migrating from the SVZ poststroke survived. Others have shown that inflammation may impair neurogenesis and its suppression may restore it. 18 -20 We used stereology and confocal microscopy to determine the immediate and long-term consequences of inflammation attributable to focal ischemia on cell proliferation and differentiation, and whether modulation of inflammation using the nonsteroidal antiinflammatory drug indomethacin influences cell genesis and histological outcome.
Materials and Methods

Focal Cerebral Ischemia
Male Sprague-Dawley rats (Charles River, Wilmington, Mass) weighing 280 to 320 g were anesthetized with 3% halothane or isoflurane plus oxygen and air (ratio: 0.2/0.8 L/min) by facemask, and maintained with 2.0% to 2.5% isoflurane. Depth of anesthesia was assessed periodically by testing for hindlimb withdrawal (and increasing anesthesia if necessary), and physiological variables were controlled. The common carotid (CCA), external carotid, and pterygopalatine arteries were exposed and ligated on the left side. The left internal carotid artery (ICA) was occluded with a microsurgical clip, and an arteriotomy was made in the CCA. A 3.0-monofilament suture (Ethicon) with a rounded tip was inserted into the CCA and advanced through the ICA to the ostium to occlude the middle cerebral artery (MCAO). After 2 hours the suture was removed, the wound was closed, and the rats were allowed to recover.
Drug Administration
Indomethacin (Sigma) was administered in rat chow (BioServ) formulated based on the rats' daily food consumption to reach a target of 2.5 mg/kg per day. Feeding with indomethacin chow began 3 days before MCAO. Untreated animals ate ordinary chow. Blood was collected from 2 rats per group on days 14 and 28 postischemia to determine serum indomethacin levels.
BrdU Administration and Tissue Preparation
Two groups received a single injection (50 mg/kg) of bromodeoxyuridine (BrdU) intraperitoneally 2 hours after onset of ischemia and were euthanized 2 hours, 1 day, or 7 days later. Other groups, including the indomethacin-treated group, were injected daily (50 mg/kg) for 6 days and euthanized on day 7, 14, or 28 after the initial BrdU injection. Brains were removed, postfixed overnight, and equilibrated in phosphatebuffered 30% sucrose. Free-floating 40-m sections were collected on a Microm cryostat and stored submerged at Ϫ20°C in 24-well plates containing a cryoprotectant composed of glycerol, ethylene-glycol, and phosphate buffered saline. BrdU labeling is intended to capture the population of cells in S-phase. Although BrdU may be incorporated into mature cells reentering the cell cycle during repair, if this occurred mature, neuronal nuclei (NeuN)ϩ cells should be present early after BrdU labeling, but they are not (see Results). Progenitor cells may also incorporate BrdU during repair, but this does not alter our conclusions because it was our goal to track the movement and fates of progenitors. 21 
Immunohistochemistry and Immunofluorescence Staining
Sections were immunostained, as previously described, 22 
Cell Counting and Unbiased Stereology
Cells were counted under a confocal microscope (Zeiss 510) in high and low GFAP-staining regions in the striatum and cortex. The GFAP region delineated the penumbra surrounding the core of the infarct (red staining in Figure 1B ). Cell phenotypes were identified by colocalization of phenotypic markers with BrdU. All counts were performed using split-panel and z-axis analyses, and multichannel configuration with a 40ϫ objective and electronic zoom of 2. When possible, at least 100 BrdUϩ cells were scored for each marker per animal. Each cell was examined in its full z-dimension and only cells with a nucleus unambiguously associated with a lineage-specific marker were scored as positive. BrdUϩ cells per GFAP-defined region were determined using diaminobenzidinestained tissues. Positive cells were scored under light microscopy using Microbrightfield Stereo Investigator software and a modification of the Fractionator method 23 corrected for overestimation using the Abercrombie method 24 for nuclei with empirically determined average diameter of 13 m.
Statistical Analysis
Statistical analysis was performed using Prism software (GraphPad). Differences between groups were assessed by ANOVA followed by the Student t test. Statistical significance was determined at the PϽ0.05 level. All data are presented as meansϮSD.
Results
Stroke Alters Proliferation in the SVZ
Transient MCAO caused infarction in the striatum and frontoparietal cortex ( Figure 1A and 1B) . The volume of the infarct was scored in the regions depicted in Figure 1D ; infarct volumes did not differ significantly across groups (PϾ0.05). Rats received a single injection of BrdU at the start of reperfusion and were euthanized 2 hours, 1 day, or 7 days postischemia. The number of cells observed 2 hours postreperfusion indexes cells transiting S-phase at that time. The number detectable at 1 and 7 days reflects additional divisions to produce BrdUϩ daughter cells, dilution of the BrdU label by extensive division, migration of cells away from the SVZ, and cell death.
Fewer BrdUϩ cells were observed bilaterally in the SVZ in ischemic animals at 2 hours postreperfusion (Figure 2A) , Figure 3 . BrdUϩ cell densities in low GFAP (A) and high GFAP (B) regions of the cortex and striatum after stroke were greater in indomethacin-treated animals than in controls (*PϽ0.05; paired t test). Indomethacin did not influence BrdUϩ cell density in sham animals. ϩ, indomethacin; Ϫ, control.
suggesting an acute suppression of cell division following MCAO. At 1 and 7 days, the number of BrdU-labeled cells in sham control animals was similar to that seen at 2 hours. At 1 and 7 days BrdUϩ cells in the contralateral SVZ of MCAO animals approximated those of sham animals, suggesting a net local gain attributable to increased cell division induced by ischemia. The number of BrdUϩ cells in the ipsilateral SVZ remained suppressed. This suggests that labeled cells were depleted from the injury-proximal SVZ by proliferative dilution of the BrdU label or migration away from the SVZ.
Many BrdUϩ were colabeled with doublecortin (DCX), a marker for migrating neuroblasts. 25 In animals subjected to stroke, many DCXϩ processes were oriented into the neighboring parenchyma ( Figure 2B and 2C) . In sham animals BrdU/DCX staining was confined to the SVZ, suggesting that in as little as 4 hours after stroke onset the distant injury triggers process extension or migration toward the injury.
Indomethacin Enhances Accumulation of Newborn Cells
Indomethacin and control rats gained weight similarly throughout the experiment. Serum indomethacin levels reached means of 2.7 g/mL and 3.7 g/mL at 14 and 28 days postischemia, approximating the human therapeutic index of 1.0 to 2.0 g/mL for the treatment of inflammatory disease. BrdUϩ cells were counted in the penumbra in sections from the rostral-caudal extent depicted in Figure 1E . GFAP staining defined the area between penumbra (high GFAP; brick red in Figure 1C ) and healthy tissue (low GFAP; light gray in Figure 1C ). 26 The ischemic core (indicated in black in Figure 1C ) had few surviving cells. BrdUϩ cells were more numerous in indomethacin-treated animals than controls 7, 14, and 28 days postischemia, both in the high-GFAP cortex (PϽ0.05; paired t test, Figure  3B ) and the high-GFAP striatum (PϽ0.05; paired t-test; Figure   3B ). Low-GFAP regions were also examined; no significant differences were observed between groups in the contralateral hemispheres, but the density of BrdUϩ cells was increased in the ischemic hemisphere in indomethacin-treated and nontreated MCAO animals at 14 and 28 days (PϽ0.05; paired t test; Figure  3A ).
Indomethacin Increases Expression of Phenotypic Markers
We sampled 100 BrdU-labeled cells per animal in high-GFAP regions in the striatum and cortex. The fraction of BrdUϩ cells expressing at least one of the markers was higher in both areas in indomethacin-treated animals than in controls at 14 and 28 days postischemia ( Figure 4A through 4C). NG2 colabeling in the cortex was most enhanced at 14 days (6.4-fold; PϽ0.05; paired t test), suggesting increased production or survival of newborn oligodendrocytes. This was followed by nestin (5.2-fold increase at 14 days; PϽ0.05; paired t test), a marker for stem-like precursor cells and immature glial and neuronal progenitors. Smaller increases were observed in GFAPϩ cells, and few BrdUϩ/NeuNϩ cells were seen in either region even 28 days after stroke. The sums of percentages ( Figure 4A and 4B) may exceed 100% because many cells expressed more than 1 lineage marker; immature glia and neurons may transiently remain nestinϩ, and some DCXϩ cells were also NG2ϩ. These cells either coexpressed these markers or immature neurons were decorated with nascent oligodendrocyte membranes as an early stage of myelination.
Net Gains in Cell Density for Each Newborn Cell Phenotype
The number of BrdUϩ cells was normalized to the volume of the scored penumbral tissue to compute the density of newborn Figure 4 . The fraction of cells that labeled with a phenotypic marker was greater in indomethacin-treated than in control animals in both cortex (A) and striatum (B). The sums of the percentages of lineage markers at 14 and 28 days sometimes exceeded 100% because many cells expressed more than one marker. ϩ, indomethacin; Ϫ, control (*PϽ0.05; ANOVA). Examples of confocal micrographs from which counts were obtained are presented in (C); these images were randomly sampled from high-GFAP regions in the cortex and striatum.
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cells in each lineage category ( Figure 5 ). Significant increases in all markers except NeuN were observed in the ischemic cortex and striatum (PϽ0.05; ANOVA). NeuNϩ cells were often closely associated with BrdUϩ cells, but the markers were rarely colocalized. A few BrdUϩ/NeuNϩ cells were found at 28 days in the penumbra of indomethacin-treated animals.
Indomethacin Reduces Inflammatory Cell Activation
Sections were stained for CD11b, a general marker for inflammatory cells. There was no significant difference in the density of microglia between treated and control animals at 7, 14, or 28 days ( Figure 6A ). We also examined tissues for ED-1ϩ cells, a marker for activated monocytes and microglia, and calculated the ratio of activated to total microglia as an indicator of local immune activation. The fraction of cells showing activation was reduced by 50% to 61% in the striatum ( Figure 6B ; PϽ0.05) and by 11% to 26% in the cortex (data not shown; PϽ0.05).
Discussion
A single pulse of BrdU 2 hours after stroke onset stained a population of cells in S-phase immediately following stroke. Our observation that the number of BrdUϩ cells was suppressed during reperfusion is novel and may indicate an acute injuryinduced suppression of proliferation resulting from oxygen/ glucose deprivation or a stroke-induced rise in circulating glucocorticoids, 27, 28 which can suppress neural progenitor proliferation. 29 -31 The density of labeled cells did not decrease 1 or 7 days later in sham control animals, even though migration via the rostral migratory stream may be expected to deplete the SVZ of labeled cells. Local cell division, producing "half-labeled" daughter cells, may have compensated for losses attributable to migration. Using longer labeling time periods, others have reported increased proliferation within the SVZ following ischemic injury, 15, 17, [32] [33] [34] and we expect that the initial suppression of proliferative activity rebounds to higher than normal levels in subsequent days. Because we examined the SVZ immediately following injury, we captured only those cells labeled through active incorporation of BrdU during reperfusion, which allowed us to observe the immediate suppression of proliferation by stroke.
To study cells born in the week following MCAO we gave daily injections of BrdU for 6 days poststroke. The number of BrdUϩ cells in high-GFAP regions of cortex and striatum of indomethacin-treated animals increased significantly above sham animals, and this increase was maintained for 28 days (Figure 3) . In low-GFAP regions of treated animals BrdU densities were significantly higher than controls at 14 and 28 days. Densities in untreated animals approximated that obtained in high-GFAP regions in the cortex and striatum at 7 days, but this increase dissipated by 14 days. Although we are unable to specify precisely where the cells originated, a recent report demonstrated that rats that received the antimitotic agent Ara-C poststroke were temporarily depleted of dividing cells in the SVZ and striatum. 14 Recovery of DCXϩ cells supported the conclusion that these cells were generated in the SVZ and migrated toward the area of injury in the striatum. Thus, many of the newborn cells we observed in the infarct penumbra may have originated in the SVZ.
Indomethacin increased the fraction of newborn cells that expressed lineage-specific markers. We observed 2-to 5-fold increases in nestin, NG2, DCX, and GFAP in high-GFAP/ BrdUϩ regions in indomethacin-treated animals. Few cells expressed NeuN. Immature DCXϩ cells may eventually mature into NeuNϩ neurons, but the severely challenged penumbra may not provide adequate cues to allow more complete differentiation.
Although the total number of microglia and monocytes (CD11bϩ cells) was not changed by indomethacin, there was a significant decrease in the fraction of these cells that were activated (ED-1ϩ). The attenuation of microglial activation is consistent with indomethacin's known action as an immunomodulatory drug and suggests that microglial activation limits the survival of newborn neural progenitor cells after stroke.
Indomethacin increased the survival of progenitor cells and allowed a higher fraction to differentiate into NG2ϩ oligodendrocytes and DCXϩ neurons. This suggests that indomethacin "releases and protects" the progenitor population. Indomethacin may exert effects at a molecular level by blocking the activation of cyclooxygenase (COX) enzymes by reactive oxygen species. 35, 36 Indomethacin inhibits COX1 and COX2, which are involved in the generation of reactive oxygen species, and also modulates signaling networks involved in inflammation such as nuclear factor B. 37 Indomethacin also agonizes the transcription factor peroxisome proliferator-activated receptor-␥, which inhibits the elaboration of proinflammatory cytokines in monocytes/microglia and contributes to neural stem cell survival. 38, 39 Our findings agree with those showing a reduction by indomethacin of ED-1ϩ inflammatory cells after hippocampal radiation injury, 19 but conflict with those showing that specific blockers for COX-2 cause a reduction in BrdUϩ cells after global ischemia. 20 Cell phenotypes were not examined in the latter study. The reduction in BrdUϩ cells may have been caused by a reduction in proliferating inflammatory cells or other nonneural cell types. COX-2 blockers also lack some effects of indomethacin such as the agonist effects on peroxisome proliferator-activated receptor-␥, which may shift the balance from death to survival in the inflammatory environment.
Overall, we have demonstrated that immunomodulation with the nonsteroidal antiinflammatory drug indomethacin substantially increases the number of surviving newborn cells after stroke, and a higher fraction of these adopt either oligodendrocyte or neuronal markers. This is a promising outcome if increased cell production and survival after stroke are functionally beneficial. 
